Innovative Ultrasound Technology in Neuromuscular Disease (AQUIRe)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02104921 |
Recruitment Status :
Completed
First Posted : April 7, 2014
Last Update Posted : March 11, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Amyotrophic Lateral Sclerosis Muscular Dystrophy Radiculopathy Myopathy Polyneuropathy and Mononeuropathies Trauma Injury Orthopedic Disorder |
Study Type : | Observational |
Actual Enrollment : | 223 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Actual Study Start Date : | December 1, 2013 |
Actual Primary Completion Date : | March 1, 2020 |
Actual Study Completion Date : | March 1, 2020 |

Group/Cohort |
---|
Neuromuscular Disease Patients
Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
|
Healthy volunteers |
- Quantitative ultrasound data, including quantified grayscale data and backscattered acoustic data [ Time Frame: 1 year ]Ultrasound data will be collected on multiple muscles in each person. The images will then be quantified using either 1. A grayscale technique in which the images themselves are analyzed via standard image software (e.g., Adobe Photoshop) as to level of echo intensity in a pre-specific region of interest or 2. the raw quantified backscatter data is captured by the transducer, expressed as a unit of power, in the same pre-specified area of interest

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- History of a well-defined, localized or generalized neuromuscular condition producing weakness or muscle atrophy, including disuse atrophy.
Exclusion Criteria:
- Multiple generalized neuromuscular conditions.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02104921
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 |
Responsible Party: | Seward Rutkove, Professor of Neurology, Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT02104921 |
Other Study ID Numbers: |
2012P000364 2K24NS060951 ( U.S. NIH Grant/Contract ) |
First Posted: | April 7, 2014 Key Record Dates |
Last Update Posted: | March 11, 2022 |
Last Verified: | March 2022 |
Muscular Dystrophies Musculoskeletal Diseases Motor Neuron Disease Amyotrophic Lateral Sclerosis Radiculopathy Polyneuropathies Mononeuropathies Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases |
Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Muscular Disorders, Atrophic Muscular Diseases Genetic Diseases, Inborn Peripheral Nervous System Diseases |